This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Actavis Appoints Industry Veterans To Lead U.S. Specialty Brands Business Units





DUBLIN, Jan. 14, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced an updated business structure for its U.S. Specialty Brands business designed to maximize the Company's newly strengthened position in key therapeutic areas and position it for continued long-term growth.

Under its new structure, Actavis' U.S. Specialty Brands business has been refocused as four business units - Women's Health, Urology/Gastroenterology (GI), Dermatology/Established Brands and Business Operations.  The Company announced the appointment of Herm Cukier to lead the U.S. Specialty Brands Women's Healthcare category, Charles Sabino, Jr., to lead the U.S. Specialty Brands Urology and GI therapeutic category, and Thomas Griffin, Jr., to lead the Business Operations team.  The Company is actively engaged in planning efforts related to the leadership of the U.S. Specialty Brands Dermatology and Established Brands business.  The four business unit leaders will report to Tim Callahan, Senior Vice President, Commercial Operations, who reports to Fred Wilkinson, President, Actavis Specialty Brands. 

"The significant increase in size and complexity of our U.S. Specialty Brands business, following the acquisition of Warner Chilcott last year, demands that we have the right structure and exceptional leadership team in place to drive our continued commercial success in the future," said Mr. Wilkinson. "We believe this business unit structure will provide the most effective way to manage our larger portfolio, provide deeper product and customer insights and deliver the necessary focus to drive continued growth in each therapeutic category within our U.S. Specialty Brands business." 

U.S. Women's Health

Actavis' U.S. Women's Health business is an industry leader with over 90 percent share of voice in oral contraceptives based on IMS Audits and a robust pipeline recently bolstered with the addition of seven new development programs encompassing three near-term launches and more than 10 products in late-stage development.  As General Manager, U.S. Women's Health, Mr. Cukier joins Actavis from Bayer, where he served most recently as Vice President, Marketing and Commercial Operations for Women's Healthcare.  Prior to his time at Bayer, he held roles as President and CEO of Reverion Pharmaceuticals, a start-up biotech company, General Manager at Schering Plough and Chief Marketing Officer at Organon.  Earlier in his career Mr. Cukier held positions of increasing commercial responsibility at Bristol Myers Squibb and Pfizer, and he holds a BSE Degree in Bioengineering from the University of Pennsylvania and a MBA in Marketing and International Business from Columbia Business School.  Mr. Cukier adds to Actavis' extensive knowledge of the Women's Health market and brings an exceptional background in U.S. and global commercialization to the Actavis organization. 

U.S. Urology & Gastroenterology

Actavis' growing Urology business markets six products in the U.S., including Rapaflo ® Androderm ® and Enablex ®.  The Company's Gastroenterology business in the U.S. is led by the Delzicol ® and Asacol HD ® franchise of products.  As General Manager, U.S. Urology and Gastroenterology, Mr. Sabino joins Actavis from Aptalis Pharma, where he most recently served as Vice President, Marketing for the specialty pharmaceutical company focused on Gastroenterology and Cystic Fibrosis treatments.  Prior to his time at Aptalis, Mr. Sabino served as Chief Operating Officer for Lipose Corp., a medical device company, and as a Managing Director for Cline, Davis & Mann, the second-largest healthcare advertising agency in the United States.  Mr. Sabino also held positions of increasing responsibility within both Pfizer and Novartis, including Executive Director of the Xolair ® respiratory franchise, and he has a MBA from Columbia Business School and a BS in Biology from Haverford College.  Mr. Sabino brings significant commercial expertise to Actavis' specialty brand business and provides a strong foundation of knowledge for Actavis' new Gastroenterology business.

U.S. Business Operations

Actavis' U.S. Business Operations group will be responsible for all shared commercial functions for the respective U.S. therapeutic business units, including sales operations, sales training, marketing research, sales analytics and managed markets field teams.  Mr. Griffin has been with Actavis since 2011 as VP, Sales and Operations for the U.S. Specialty Brands business.  Prior to joining Actavis, Mr. Griffin was VP, Sales for Bayer Diabetes Care from 2008 to 2010, and prior to that spent 19 years in the Pfizer sales organization in positions of increasing responsibility, culminating as Senior VP Sales for the Urology-Respiratory Therapeutic Cluster.  Mr. Griffin brings exceptional sales leadership, operations and managed markets expertise to this newly created U.S. Business Operations unit.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs